filmov
tv
Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis
Показать описание
Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).
Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis
Dr. Wong on the Difficulty of Diagnosing Patients With AL Amyloidosis
Dr. Wong Discusses Monoclonal Antibodies in Plasma Cell Neoplasms
Growing amyloid fibrils in the lab
The potential of anti-amyloid antibodies to treat amyloidosis
AL amyloidosis special session highlights: therapeutic advances and ongoing trials in the field
Insights into the management of systemic AL amyloidosis
Dr. Wong Discusses the FDA Approval of Elotuzumab Triplet in Myeloma
New antibody treatments for AL amyloidosis
Investigating links between anti-depressants and Alzheimer’s pathology
Birtamimab (NEOD001): changing the treatment of amyloidosis
Alzheimers A4 Study - Anti-Amyloid Treatment in Asymptomatic Alzheimer
Future AL amyloidosis treatment
NEOD001: The VITAL Amyloidosis Study
Alzheimer's Disease Pt 1
Game-changing drugs for amyloidosis treatment
Early diagnosis and optimal treatment of AL amyloidosis
Promising Cardiac and Renal Responses with NEOD001 in Patients with AL Amyloidosis
Advances in Alzheimer's disease biomarkers & therapies
AA amyloidosis management
ARC Talks: Stem Cell Transplantation in AL Amyloidosis
Into and Beyond Clonal Plasma Cells in AL Amyloidosis
AL Amyloidosis
Progress With Monoclonal Antibodies in Plasma Cell Neoplasms
Комментарии